<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103306</url>
  </required_header>
  <id_info>
    <org_study_id>CBNUH-LUCID</org_study_id>
    <nct_id>NCT05103306</nct_id>
  </id_info>
  <brief_title>Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy</brief_title>
  <acronym>LUCID</acronym>
  <official_title>Long-term Effectiveness and Safety of Empagliflozin-based Quadruple Oral Antidiabetic Agents Therapy Compared to Basal Insulin-based Combination Therapy in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chungbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chungbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as&#xD;
      add-on thearpy compared to basal insulin-based antidiabetic agents (OADs) combination therapy&#xD;
      in patients with type 2 diabetes inadequately controlled on triple OADs in a real clinical&#xD;
      practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aimed to evaluate the long-term effectiveness and safety of the empagliflozin as&#xD;
      add-on thearpy compared to basal insulin-based antidiabetic agents (OADs) combination therapy&#xD;
      in patients with type 2 diabetes inadequately controlled on triple OADs in a real clinical&#xD;
      practice.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Changes in HbA1c From Baseline to months 36</measure>
    <time_frame>Baseline, month 36 (3-year)</time_frame>
    <description>Changes in HbA1c From Baseline to months 36 (3-year)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achievement of target HbA1c</measure>
    <time_frame>Baseline, month 36</time_frame>
    <description>Percentage of Patients Who Achieved Glycemic Target of HbA1c at month 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HbA1c</measure>
    <time_frame>Baseline, month 3, 6, 12, 18, 24, 30</time_frame>
    <description>Changes in HbA1c From Baseline to each time frame</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FPG</measure>
    <time_frame>Baseline, month 3, 6, 12, 18, 24, 30, 36</time_frame>
    <description>Changes in fasting plasma glucose level from baseline to each month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in lipid profiles</measure>
    <time_frame>Baseline, month 36</time_frame>
    <description>Changes in total cholesterol, triglyceride, HDL-cholesterol and LDL cholesterol from baseline to month 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in body weight</measure>
    <time_frame>Baseline, month 36</time_frame>
    <description>Changes in body weight from baseline to month 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>Baseline, month 36</time_frame>
    <description>Changes in systolic and diastolic blood pressure from baseline to month 36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with hypoglycemic episodes</measure>
    <time_frame>Baseline, month 36</time_frame>
    <description>All episodes consistent with hypoglycemia with or without a confirmatory blood glucose reading were collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least 1 episode of genitourinary tract infections</measure>
    <time_frame>Baseline, month 36</time_frame>
    <description>Percentage of Patients With At Least 1 Episode of Genitourinary Tract Infections</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Triple OADs failure</arm_group_label>
    <description>Inadequatelly controlled type 2 diabetes patients despite triple combination therapy with metformin, glimepiride, and DPP-4 inhibitor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin 25 MG</intervention_name>
    <description>Empagliflozin 25mg/day add-on to triple combination oral antidiabetic agents consisted with metformin, glimepiride, and DPP4 inhibitor</description>
    <arm_group_label>Triple OADs failure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS</intervention_name>
    <description>Basal insulin add on the background OADs</description>
    <arm_group_label>Triple OADs failure</arm_group_label>
    <other_name>Basal insulin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetes, uncontrolled with triple OADs&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inadequately controlled with triple OADs (metformin, glimepiride, dipeptidyl&#xD;
             peptidase-4 inhibitor) showing HbA1c 7.5-12.0%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes&#xD;
&#xD;
          -  Gestional diabetes&#xD;
&#xD;
          -  Diabetes due to secondary causes&#xD;
&#xD;
          -  Receiving anticancer treatment&#xD;
&#xD;
          -  Receiving glucocorticoids or immune-suppressants&#xD;
&#xD;
          -  Have been treated with sodium glucose co-transporter 2 inhibitors for more than 7&#xD;
             consecutive days within 3 months before entering the study&#xD;
&#xD;
          -  Have been treated with any type of insulin for more than 7 consecutive days within 3&#xD;
             months before entering the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eu Jeong Ku, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk National University Hospital</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chungbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Eu Jeong Ku</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Type 2 diabetes mellitus</keyword>
  <keyword>Sodium-glucose co-transporter 2 inhibitor</keyword>
  <keyword>Empagliflozin</keyword>
  <keyword>Insulin glargine</keyword>
  <keyword>Insulin degludec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

